MalÃº GÃ¡mez Tansey

List of Publications by Year
in descending order

108 papers	7,768 citations	71102 41 h-index	54911 84 g-index
127 all docs	127 docs citations	127 times ranked	9680 citing authors

#	Article	IF	Citations
1	Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiology of Disease, 2010, 37, 510-518.	4.4	879
2	TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. Journal of Neuroinflammation, 2008, 5, 45.	7.2	698
3	The gut-brain axis: is intestinal inflammation a silent driver of Parkinsonâ€™s disease pathogenesis?. Npj Parkinson's Disease, 2017, 3, 3.	5.3	388
4	Inflammation and immune dysfunction in Parkinson disease. Nature Reviews Immunology, 2022, 22, 657-673.	22.7	360
5	Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease. Journal of Neuroscience, 2006, 26, 9365-9375.	3.6	331
6	What does plasma CRP tell us about peripheral and central inflammation in depression?. Molecular Psychiatry, 2020, 25, 1301-1311.	7.9	251
7	The Role of Innate and Adaptive Immunity in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 493-514.	2.8	249
8	Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration. Journal of Neuroscience, 2008, 28, 10825-10834.	3.6	240
9	Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiology of Disease, 2009, 34, 163-177.	4.4	236
10	Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants. Science, 2003, 301, 1895-1898.	12.6	222
11	Microglial phenotypes in Parkinsonâ€™s disease and animal models of the disease. Progress in Neurobiology, 2017, 155, 57-75.	5.7	202
12	Neuroimmunological Processes in Parkinson's Disease and their Relation to Î±-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity. ASN Neuro, 2013, 5, AN20120066.	2.7	197
13	Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2021, 16, 6.	10.8	197
14	Peripheral and central immune system crosstalk in Alzheimer disease â€” a research prospectus. Nature Reviews Neurology, 2021, 17, 689-701.	10.1	169
15	Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. Journal of Neuroinflammation, 2018, 15, 129.	7.2	131
16	Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. Movement Disorders, 2018, 33, 793-804.	3.9	130
17	Toll-like Receptor 4 Mediates Morphine-Induced Neuroinflammation and Tolerance via Soluble Tumor Necrosis Factor Signaling. Neuropsychopharmacology, 2017, 42, 661-670.	5.4	111
18	Intranigral Lentiviral Delivery of Dominant-negative TNF Attenuates Neurodegeneration and Behavioral Deficits in Hemiparkinsonian rats. Molecular Therapy, 2008, 16, 1572-1579.	8.2	106

#	Article	IF	Citations
19	Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiology of Disease, 2017, 102, 81-95.	4.4	104
20	Immune system responses in Parkinson's disease: Early and dynamic. European Journal of Neuroscience, 2019, 49, 364-383.	2.6	104
21	LRRK2 regulation of immune-pathways and inflammatory disease. Biochemical Society Transactions, 2019, 47, 1581-1595.	3.4	97
22	Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B. PLoS ONE, 2011, 6, e23660.	2.5	96
23	Delayed Dominant-Negative TNF Gene Therapy Halts Progressive Loss of Nigral Dopaminergic Neurons in a Rat Model of Parkinson's Disease. Molecular Therapy, 2011, 19, 46-52.	8.2	94
24	Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimerâ€™s disease associated with obesity, metabolic syndrome, and type 2 diabetes. Alzheimer's Research and Therapy, 2020, 12, 1.	6.2	91
25	Regulator of G-Protein Signaling 10 Promotes Dopaminergic Neuron Survival via Regulation of the Microglial Inflammatory Response. Journal of Neuroscience, 2008, 28, 8517-8528.	3.6	87
26	Lysosome and Inflammatory Defects in GBA1â€Mutant Astrocytes Are Normalized by LRRK2 Inhibition. Movement Disorders, 2020, 35, 760-773.	3.9	79
27	Peripheral Administration of the Selective Inhibitor of Soluble Tumor Necrosis Factor (TNF) XProÂ®1595 Attenuates Nigral Cell Loss and Glial Activation in 6-OHDA Hemiparkinsonian Rats. Journal of Parkinson's Disease, 2014, 4, 349-360.	2.8	74
28	Chronic psychological stress and high-fat high-fructose diet disrupt metabolic and inflammatory gene networks in the brain, liver, and gut and promote behavioral deficits in mice. Brain, Behavior, and Immunity, 2017, 59, 158-172.	4.1	74
29	Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. JCI Insight, 2017, 2, .	5.0	72
30	Genetic and Environmental Factors in <scp>P</scp>arkinson's Disease Converge on Immune Function and Inflammation. Movement Disorders, 2021, 36, 25-36.	3.9	69
31	Neuroinflammation and Non-motor Symptoms: The Dark Passenger of Parkinsonâ€™s Disease?. Current Neurology and Neuroscience Reports, 2012, 12, 350-358.	4.2	68
32	Regulator of G-Protein Signaling-10 Negatively Regulates NF-ÎºB in Microglia and Neuroprotects Dopaminergic Neurons in Hemiparkinsonian Rats. Journal of Neuroscience, 2011, 31, 11879-11888.	3.6	64
33	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinsonâ€™s disease. Journal of Neuroinflammation, 2017, 14, 164.	7.2	64
34	TNF: A Key Neuroinflammatory Mediator of Neurotoxicity and Neurodegeneration in Models of Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2011, 691, 539-540.	1.6	59
35	The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Human Molecular Genetics, 2015, 24, 4250-4267.	2.9	58
36	A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. Journal of Neuroinflammation, 2017, 14, 128.	7.2	58

#	Article	IF	Citations
37	Interactions Between Commensal Bacteria and Enteric Neurons, via FPR1 Induction of ROS, Increase Gastrointestinal Motility inÂMice. Gastroenterology, 2019, 157, 179-192.e2.	1.3	58
38	Regulation of microglia effector functions by tumor necrosis factor signaling. Glia, 2012, 60, 189-202.	4.9	53
39	Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36. Neuron, 2020, 107, 292-305.e6.	8.1	51
40	Molecular Signatures of Neuroinflammation Induced by Î±Synuclein Aggregates in Microglial Cells. Frontiers in Immunology, 2020, 11, 33.	4.8	50
41	A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets. Experimental Neurology, 2014, 256, 126-132.	4.1	49
42	LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinsonâ€™s. Frontiers in Neuroscience, 2020, 14, 443.	2.8	47
43	Is LRRK2 the missing link between inflammatory bowel disease and Parkinsonâ€™s disease?. Npj Parkinson's Disease, 2021, 7, 26.	5.3	46
44	Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms. Movement Disorders, 2022, 37, 1644-1653.	3.9	44
45	Potential Role of the Gut Microbiome in ALS: A Systematic Review. Biological Research for Nursing, 2018, 20, 513-521.	1.9	42
46	Chronic adolescent stress sex-specifically alters central and peripheral neuro-immune reactivity in rats. Brain, Behavior, and Immunity, 2019, 76, 248-257.	4.1	42
47	A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain, 2022, 145, 1924-1938.	7.6	39
48	Critical Role of Regulator G-Protein Signaling 10 (RGS10) in Modulating Macrophage M1/M2 Activation. PLoS ONE, 2013, 8, e81785.	2.5	37
49	An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 242-249.	1.7	35
50	Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series. Neurobiology of Disease, 2020, 144, 105027.	4.4	34
51	Two weeks of predatory stress induces anxiety-like behavior with co-morbid depressive-like behavior in adult male mice. Behavioural Brain Research, 2014, 275, 120-125.	2.2	33
52	Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. Acta Neuropathologica Communications, 2021, 9, 139.	5.2	33
53	Transgenic Mice Expressing Human Î±-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease. Journal of Neuroscience, 2020, 40, 7559-7576.	3.6	32
54	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinsonâ€™s Disease. Molecules, 2020, 25, 453.	3.8	30

#	Article	IF	Citations
55	Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 91-99.	1.7	30
56	RGS10 exerts a neuroprotective role through the PKA/câ€AMP responseâ€element (CREB) pathway in dopaminergic neuronâ€like cells. Journal of Neurochemistry, 2012, 122, 333-343.	3.9	29
57	Î±-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinsonâ€™s Disease Pathogenesis. Frontiers in Neuroscience, 2018, 12, 626.	2.8	28
58	Spinal motor circuit synaptic plasticity after peripheral nerve injury depends on microglia activation and a CCR2 mechanism. Journal of Neuroscience, 2019, 39, 2945-17.	3.6	27
59	RGS10 Negatively Regulates Platelet Activation and Thrombogenesis. PLoS ONE, 2016, 11, e0165984.	2.5	27
60	RGS10 deficiency ameliorates the severity of disease in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2016, 13, 24.	7.2	24
61	Adolescent stress sensitizes the adult neuroimmune transcriptome and leads to sex-specific microglial and behavioral phenotypes. Neuropsychopharmacology, 2021, 46, 949-958.	5.4	22
62	Physiology of RGS10 in Neurons and Immune Cells. Progress in Molecular Biology and Translational Science, 2015, 133, 153-167.	1.7	18
63	Age-related changes in regulator of G-protein signaling (RGS)-10 expression in peripheral and central immune cells may influence the risk for age-related degeneration. Neurobiology of Aging, 2015, 36, 1982-1993.	3.1	18
64	Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimerâ€™s (HEART) Trial. Journal of Alzheimer's Disease, 2017, 61, 815-824.	2.6	18
65	Chronic psychological stress during adolescence induces sex-dependent adulthood inflammation, increased adiposity, and abnormal behaviors that are ameliorated by selective inhibition of soluble tumor necrosis factor with XPro1595. Brain, Behavior, and Immunity, 2019, 81, 305-316.	4.1	15
66	Role of the Innate and Adaptive Immune System in the Pathogenesis of PD. , 2014, , 75-103.		14
67	WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinsonâ€™s Disease Monocytes. Frontiers in Cellular Neuroscience, 0, 16, .	3.7	13
68	Selective effects of a therapeutic protein targeting tumor necrosis factorâ€alpha on cytochrome P450 regulation during infectious colitis: implications for diseaseâ€dependent drugâ€“drug interactions. Pharmacology Research and Perspectives, 2014, 2, e00027.	2.4	11
69	Inflammatory mechanisms contribute to microembolism-induced anxiety-like and depressive-like behaviors. Behavioural Brain Research, 2016, 303, 160-167.	2.2	11
70	Parkinsonism without dopamine neuron degeneration in aged <scp>l</scp>â€dopaâ€responsive dystonia knockin mice. Movement Disorders, 2017, 32, 1694-1700.	3.9	11
71	Poldip2 controls leukocyte infiltration into the ischemic brain by regulating focal adhesion kinase-mediated VCAM-1 induction. Scientific Reports, 2021, 11, 5533.	3.3	10
72	TNFÎ± increases tyrosine hydroxylase expression in human monocytes. Npj Parkinson's Disease, 2021, 7, 62.	5.3	10

#	ARTICLE	IF	CITATIONS
73	AAV-Dominant Negative Tumor Necrosis Factor (DN-TNF) Gene Transfer to the Striatum Does Not Rescue Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease. PLoS ONE, 2014, 9, e96544.	2.5	9
74	Linking mitochondria to the immune response. ELife, 2020, 9, .	6.0	9
75	The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss. Experimental Neurology, 2019, 318, 157-164.	4.1	7
76	Challenges in Passive Immunization Strategies to Treat Parkinson Disease. JAMA Neurology, 2018, 75, 1180.	9.0	5
77	Characterization of a Cul9â€“Parkin double knockout mouse model for Parkinsonâ€™s disease. Scientific Reports, 2020, 10, 16886.	3.3	5
78	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. Alzheimer's and Dementia, 2022, 18, 178-190.	0.8	5
79	Inflammation-Related Factors Identified as Biomarkers of Dehydration and Subsequent Acute Kidney Injury in Agricultural Workers. Biological Research for Nursing, 2021, 23, 676-688.	1.9	5
80	The gut microbiome and neuroinflammation in amyotrophic lateral sclerosis? Emerging clinical evidence. Neurobiology of Disease, 2020, 135, 104300.	4.4	4
81	Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice. Communications Biology, 2022, 5, 446.	4.4	4
82	Infection triggers symptoms similar to those of Parkinsonâ€™s disease in mice lacking PINK1 protein. Nature, 2019, 571, 481-482.	27.8	2
83	Editorial for Special issue on Microbiome in neurological and psychiatric disease. Neurobiology of Disease, 2020, 135, 104699.	4.4	2
84	Loss of progranulin leads to dysregulation of innate and adaptive immune cell populations, increased susceptibility to experimental colitis, and brain infiltration of peripheral immune cells. Alzheimer's and Dementia, 2020, 16, e042177.	0.8	2
85	Inhibition of soluble TNF protects mice against brain inflammation and demyelination in a cuprizone model for multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 182.	2.3	1
86	LRRK2. , 2017, , 107-116.		1
87	P4â€480: WESTERN DIET PROMOTES CENTRAL INSULIN IMPAIRMENT AND THE DYSREGULATION OF METABOLITES ASSOCIATED WITH ALZHEIMER'S DISEASE: THE ROLE OF SOLUBLE TNF. Alzheimer's and Dementia, 2019, 15, P1496.	0.8	1
88	P4-205: Peripheral administration of the novel tnf inhibitor xpro1595 improves synaptic function in the 5XFAD model of Alzheimer's disease. , 2015, 11, P859-P859.		0
89	Pesticide-induced Immunotoxicity May Underlie Synergistic Gene-environment Interactions that Increase Parkinson's Disease Risk for High-risk Genotype Individuals at rs3129882 in the HLA-DRA Gene. Journal of Clinical & Cellular Immunology, 2016, 07, .	1.5	0
90	P3-069: Elucidating the Relationship Between Hyperphosphorylated TAU and Locus Coeruleus Degeneration in Alzheimerâ€™s Disease. , 2016, 12, P844-P844.		0

#	ARTICLE	IF	CITATIONS
91	[O2â€“15â€“03]: ELEVATED CENTRAL AND PERIPHERAL INFLAMMATORY PROFILES IN A POPULATION AT RISK FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P594.	0.8	0
92	[P2â€“090]: ROLE OF SOLUBLE TNF IN DIETâ€INDUCED PERIPHERAL AND CENTRAL INFLAMMATION IN A MOUSE MODEL OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P641.	0.8	0
93	O2â€1 1â€02: THE ROLE OF SOLUBLE TNF IN METABOLIC DYSFUNCTION AND BBB ALTERATIONS IN A MOUSE MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P647.	0.8	0
94	O2â€1 1â€03: PROGRANULIN LOSS DYSREGULATES SPLENIC AND PERIPHERAL BLOOD IMMUNE CELL POPULATIONS AND MAY CONTRIBUTE TO NEUROINFLAMMATION AND NEURODEGENERATION IN FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P647.	0.8	0
95	Neuroinflammation in Age-Related Neurodegenerative Diseases. , 2018, , 477-507.		0
96	Soluble TNF mediates highâ€fat and highâ€carbohydrate dietâ€“induced inflammation, alterations in peripheral blood and brain immunophenotype, and gut microbiome in a mouse model of amyloid pathology. Alzheimer's and Dementia, 2020, 16, e040436.	0.8	0
97	Synaptoprotective effects of the novel TNF inhibitor XPRO1595 in 5xFAD mice: Interactions between Western diet and sex. Alzheimer's and Dementia, 2020, 16, e043621.	0.8	0
98	Topâ€line data from a phase 1b biomarkerâ€directed, proof of biology study in Alzheimer's patients treated with XPRO1595, a secondâ€generation treatment for immune dysfunction. Alzheimer's and Dementia, 2020, 16, e046037.	0.8	0
99	RNA-SEQ REVEALS HSP90 AS A REGULATOR FOR INTERLEUKIN 6-MEDIATED ACTIVATION OF NCC VIA THE MINERALOCORTICOID RECEPTOR. Journal of Hypertension, 2021, 39, e49.	0.5	0
100	Interleukinâ€6 Mediated Regulation of ENaC via Timeâ€Dependent MAPK Family Activation. FASEB Journal, 2021, 35, .	0.5	0
101	Workshop Summary: Roles of the TNF Family in Neuronal Development, Function and Pathology. Advances in Experimental Medicine and Biology, 2011, 691, 537-538.	1.6	0
102	Effect of High Fat High Fructose Diet on Peripheral Immune Cell Trafficking into the Brain in CCR2 Mouse Model. FASEB Journal, 2018, 32, 740.10.	0.5	0
103	Lactobacilli â€induced Generation of Reactive Oxygen Species via Formyl Peptide Receptorâ€1 (FPR1) Regulates Intestinal Motility in Mice. FASEB Journal, 2019, 33, 763.1.	0.5	0
104	Interleukinâ€6 Induced Differential Gene Expression in mDCT15 Cells. FASEB Journal, 2020, 34, 1-1.	0.5	0
105	Molecular signatures of neuroinflammation induced by Î±â€synuclein aggregates in microglial cells. FASEB Journal, 2020, 34, 1-1.	0.5	0
106	Assessing stimulation-dependent changes in LRRK2 and GCase expression/activity and convergence at the lysosome in cryopreserved monocytes.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054214.	0.8	0
107	The role of cannabinoid receptor 2 in microglial clearance of human tau.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054361.	0.8	0
108	The role of soluble TNF in mediating immune and metabolic alterations in a mouse model of amyloid-beta pathology.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055753.	0.8	0